Related Experiment Video
Updated: Nov 1, 2025
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
8.0K
Biomarkers for differentiating grade II meningiomas from grade I: a systematic review
Agbolahan A Sofela1,2, Lucy McGavin3, Peter C Whitfield2
1Faculty of Health: Medicine, Dentistry and Human Sciences, The Institute of Translational and Stratified Medicine, University of Plymouth, Plymouth, UK.
British Journal of Neurosurgery
|June 21, 2021
Summary
New biomarkers may help predict meningioma grade before surgery. Radiological and blood markers can differentiate grade II from grade I meningiomas, potentially personalizing treatment for better patient outcomes.
Area of Science:
- Neuro-oncology
- Neurosurgery
- Pathology
Background:
- Meningiomas lack validated preoperative biomarkers for grade prediction.
- Accurate grading is crucial for treatment decisions, especially for controversial grade II tumors.
- Current grading relies on post-surgical histological analysis.
Purpose of the Study:
- To review potential clinical biomarkers for differentiating grade II from grade I meningiomas.
- To identify radiological, biochemical, and immunohistochemical markers for diagnosis and prognosis.
- To assess their utility in preoperative meningioma assessment.
Main Methods:
- Systematic literature review of PUBMED, SCOPUS, OVID SP, SciELO, and INFORMA.
- Keywords included 'biomarker', 'diagnosis', 'atypical', 'meningioma', 'prognosis', 'grade I', 'grade 1', 'grade II', 'grade 2'.
- Focused on studies published post-2016, adhering to WHO classification.
Main Results:
- Identified radiological markers: irregular shape, rapid growth (>3cm³/year), high peri-tumoral blood flow.
- Identified blood markers: low serum TIMP1/2, high serum HER2, high plasma Fibulin-2.
- Identified histological markers: low H3K27me3, low SMARCE1, low AKAP12, high ARIDB4.
Conclusions:
- Radiological and blood markers may enable preoperative grade prediction, influencing treatment intensity.
- Histological markers could prognosticate tumor progression or recurrence.
- These biomarkers offer a path towards personalized meningioma management.
